May 2026 brought neurotoxin innovation (a recombinant toxin abroad, "microtox" research), a wave of GLP-1 trials and indications, and a quiet countdown to July's peptide review.
May 2026 moved all three injectable tiers: neurotoxin innovation (a recombinant toxin approved abroad and new "microtox" research), a wave of GLP-1 clinical data and new indications, and a quiet peptide countdown toward July's compounding review.
After a headline-heavy April, May was a month of clinical depth across the tiers.
Tier 1 (aesthetic injectables). The neurotoxin category showed unusual movement: a recombinant botulinum toxin was reported approved in China, and a May study formalized "microtox" (MBT) for skin quality. The broader trend stayed fixed on "high-fidelity," undetectable results, skin boosters, and biostimulator-driven regeneration.
Tier 2 (GLP-1). A data wave defined the month: the oral landscape widened (an oral semaglutide tablet became available May 1), retatrutide reported up to ~28% weight loss in Phase 3, two maintenance trials (in Nature Medicine and The Lancet) tackled weight regain, a study pushed back on the "muscle loss" worry, and signals continued for indications beyond weight (including behavioral and metabolic effects).
Tier 3 and men's health. AUA 2026 data linked GLP-1s to higher testosterone in men, while peptides settled into a waiting period ahead of July's PCAC compounding review.
Cutting across all of it, a May safety report underscored that a counterfeit and gray-market threat persists even as legal options expand.
WHY IT MATTERS The throughline is maturation: deeper evidence, new formulations, and a clearer regulatory roadmap, alongside a persistent safety message. For consumers, the same two questions endure, is the provider qualified, and is the product authentic and appropriate?